Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

AI drug discovery stories

Oct 13, 2026

Zealand Pharma partners with Generate Biomedicines on AI obesity drug development worth up to $1.2 billion

Danish obesity-drug developer Zealand Pharma partnered with US biotech company Generate Biomedicines to develop protein-based treatments for obesity and metabolic diseases using AI, in a deal valued at up to $1.2 billion.

Oct 13, 2026·2 sources
00
Sep 16, 2026

ByteDance raises $290 million for spun-off AI drug discovery unit at $1.5 billion valuation

Chinese internet company ByteDance has completed a $290 million fundraising round for its artificial intelligence drug discovery unit after spinning it off as a separate entity called Anew Labs. The funding values the newly independent company at $1.5 billion.

Sep 16, 2026·3 sources
00

Top claims

  • ▪Zealand Pharma is jointly developing the obesity drug petrelintide with Roche under a 2025 agreement worth up to $5.3 billion
  • ▪Multispecific protein therapies offer a superior treatment model for obesity than single-target GLP-1 drugs
  • ▪Danish developer Zealand Pharma partnered with US biotechnology company Generate Biomedicines to develop AI-based protein treatments for obesity and metabolic diseases in a deal worth up to $1.2 billion

Topics

Obesity treatmentAI applicationsCorporate spin-offsAI for developersVenture capital fundingAI startupsLongevity biotech founders

Related entities

United StatesChina